The combination of sacituzumab govitecan (Trodelvy) and pembrolizumab (Keytruda) offered a manageable and predictable safety profile in patients with previously untreated, PD-L1–positive metastatic triple-negative breast cancer (TNBC),…
Sacituzumab Govitecan/Pembrolizumab Offers Manageable, Predictable Safety Profile in TNBC | Targeted Oncology
